Cencora, Inc. (NYSE:COR) Stock Holdings Lessened by Beacon Pointe Advisors LLC

Beacon Pointe Advisors LLC trimmed its position in Cencora, Inc. (NYSE:COR - Free Report) by 43.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,490 shares of the company's stock after selling 1,147 shares during the period. Beacon Pointe Advisors LLC's holdings in Cencora were worth $335,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. JFS Wealth Advisors LLC grew its holdings in Cencora by 63.0% in the fourth quarter. JFS Wealth Advisors LLC now owns 119 shares of the company's stock valued at $27,000 after purchasing an additional 46 shares during the period. SBI Securities Co. Ltd. acquired a new position in shares of Cencora during the 4th quarter valued at $30,000. Kentucky Trust Co purchased a new stake in Cencora during the 4th quarter worth $33,000. Householder Group Estate & Retirement Specialist LLC raised its position in Cencora by 85.2% in the fourth quarter. Householder Group Estate & Retirement Specialist LLC now owns 150 shares of the company's stock valued at $33,000 after purchasing an additional 69 shares during the period. Finally, WASHINGTON TRUST Co raised its holdings in shares of Cencora by 37.7% during the 4th quarter. WASHINGTON TRUST Co now owns 168 shares of the company's stock valued at $38,000 after buying an additional 46 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Stock Performance

COR stock traded up $13.23 during mid-day trading on Wednesday, reaching $304.04. The company had a trading volume of 2,384,298 shares, compared to its average volume of 1,509,714. The stock's 50-day simple moving average is $274.32 and its two-hundred day simple moving average is $252.29. The stock has a market capitalization of $58.96 billion, a P/E ratio of 43.25, a P/E/G ratio of 1.31 and a beta of 0.60. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40. Cencora, Inc. has a one year low of $214.77 and a one year high of $308.93.

Cencora (NYSE:COR - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, topping the consensus estimate of $4.07 by $0.35. The firm had revenue of $75.50 billion during the quarter, compared to analysts' expectations of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. Cencora's quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $3.80 EPS. Research analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 5,000 shares of the firm's stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company's stock, valued at approximately $3,724,197.76. This trade represents a 24.54 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Lazarus Krikorian sold 2,000 shares of the company's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the sale, the chief accounting officer now directly owns 20,154 shares of the company's stock, valued at approximately $5,241,249.24. This represents a 9.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 50,223 shares of company stock valued at $13,580,967 in the last quarter. Corporate insiders own 10.80% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. StockNews.com upgraded shares of Cencora from a "hold" rating to a "buy" rating in a research note on Wednesday, March 12th. Evercore ISI lifted their price objective on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, February 6th. UBS Group upped their price target on shares of Cencora from $298.00 to $335.00 and gave the company a "buy" rating in a report on Tuesday, April 29th. JPMorgan Chase & Co. boosted their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research report on Friday, January 24th. Finally, Bank of America increased their price target on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $290.00.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.